2026-06-24 14:25:04
GLP-1 medications generate large weight loss and may also alter social and economic outcomes. Using the Understanding America Study, I compare women starting GLP-1s for weight loss with matched women who would like to start a GLP-1 but have not. Single women’s marriage/cohabitation rates rise by 29 percentage points and employment among baseline non-employed women rises 27 percentage points after six or more quarters. Existing partnerships do not dissolve, and already-employed women show no upward job mobility. The pattern suggests that part of the female obesity penalty operates at new-match formation rather than only through health or incumbent productivity.
Here is the paper by Rebecca Diamond. And here is a thread on the paper. And not everyone believes the size of these estimates. I do not find them so crazy? Here is Steven’s dialogue with GPT.
The post GLP-1 drugs and marriage appeared first on Marginal REVOLUTION.
2026-06-24 13:17:02
Aliaksandra Melnichenka, Belarus/Kentucky, to support science and math writing.
Guilherme Pinho, Sao Paulo, real estate titling and transactions in Brazil.
Diyar Zhakpelov, Astana, Kazakhstan, 17, exam prep app for Kazakhs, general career support.
Randy Chang, AI policy writings, Ontario/Chapel Hill.
Jesse Casana, Dartmouth, archaeology tranche, “Drone-acquired synthetic aperture radar (SAR), a novel and experimental technology, reveals remarkable perspectives on buried archaeological landscapes in the desert southwest.”
Gia-Bao Dam, New Haven/Yale, longevity research.
Sasha Lempers, Annecy, France, 15, math and AI.
Ali-Mansur Valiyev, Harihar Rengan, Dubai, high school, general career support, educational testing.
Raiani Romanni-Klein, Boston/Cambridge, a non-profit on the implications of biological innovation.
Clara Collier, Oakland, Asterisk magazine.
Scott Ellis, Mississauga, science education tranche, biographies of scientists on YouTube.
Jim Olds, northern Virginia, writings on science policy, science education tranche.
The post Emergent Ventures winners, 55th cohort appeared first on Marginal REVOLUTION.
2026-06-24 00:46:01
1. This paper was presented 57 different times!? Is that good or bad?
2. Benny Goodman and Lionel Hampton doing “I Got Rhythm.”
3. Claims about advancements in cancer testing.
4. Reconstructing Welles’s Don Quixote?
5. The obesity penalty in political elections.
6. Zvi on GLM-5.2.
7. New work by Mozart. And more information here.
8. Chad Jones going on leave to Anthropic.
The post Tuesday assorted links appeared first on Marginal REVOLUTION.
2026-06-23 19:19:28
The HHS (FDA, NIH, ARPA-H and related agencies) is moving to speed clinical trials in what they are calling Operation TrialBlazer (kudos on the pun). The motivator, of course, is China:
China has made biotechnology a strategic national priority, systematically expanding its clinical research infrastructure with government backing, streamlined regulatory pathways, and sustained investment. In 2021, China’s global share of Phase 1 trials surpassed the United States’ share for the first time, a milestone that would have seemed unlikely just a decade earlier. And in 2024, China surpassed the United States in the total number of clinical trials registered, with over 7,100 registered, representing 39% of global trials…. For certain cutting edge modalities, including cell and gene therapy, radioligand therapy, and stem cell therapy, China uses investigator-initiated trials to provide additional flexibility, though with some tradeoffs around oversight and quality control. This means that drugs can move into human testing if a researcher has an interest and funding. In the U.S., comparable trials might wait years to start.
I am also pleased to see that they mention Australia, another advanced democracy, as a leader in clinical trial regulation:
Australia’s Clinical Trial Notification System allows trials to begin in fewer than 70 days after a final protocol is submitted, with regulatory approval granted in as little as 21 to 28 days and sites activated within 6 to 12 weeks.
Keep those comparisons in mind. Operation TrialBlazer proposes some good reforms such as CMC clarification. CMC is Chemistry, Manufacturing, and Controls–and it deals with the basics of manufacturing a drug. The FDA, however, is very risk averse and companies know that so they have often gone overboard in CMC: for example, proving stability of a formula at 6+ months when the trial is to last only a few weeks or documenting their full commercial manufacturing process before they even know if the drug works and knowing full-well that the process will be changed many times before a drug actually gets to market. In short, a lot of cost for very little benefit. The FDA is now clarifying that this kind of thing is not necessary. Good, that is low-hanging fruit. There are other good ideas as well.
But note what they are not proposing. Despite using China and Australia as exemplars they are not going down either path. Where China is fastest is in cell therapy, gene therapy, radioligand, and stem cell work and in these areas, China lets trials proceed on an investigator-initiated basis: as the TrialBlazer document puts it, a drug can move into humans “if a researcher has an interest and funding.” China then combines this open (or lax) front end (for these products) with an all-of-government industrial policy to accelerate winners.
The US is declining to go down that path. Ok, not my call, but I get it. But they are also declining to follow Australia. In Australia there is also no government prospective regulatory evaluation of most early-phase clinical trials. Under the Clinical Trial Notification (CTN) scheme, the sponsor submits their protocol package to a Human Research Ethics Committee (HRECs)–Australia’s IRBs–and once the ethics committee approves, the sponsor notifies the regulator, the Therapeutic Goods Administration (TGA), and pays a fee. The TGA does not read and clear the package before the trial starts. The roughly 21-to-28-day “approval” and sub-70-day start figures in the document are fast precisely because the regulatory step is not an evaluation. The government regulator stays out of the front end for most clinical trials, although in direct contrast with China it does step in for the highest risk biologicals. China has decided, high-risk, high-reward.
Australia does certify the certifiers, the HRECs. Europe uses a similar system for medical device approval. It’s a system proposed by former medical officer at the FDA Henry Miller and one I have long supported for the US. China is more laissez-faire.
The US architecture in contrast rests on the “gold standard” FDA reviews and the “FDA will retain full regulatory authority and decision-making.” In short, all of the TrialBlazer reforms are about making the gatekeeper faster, cheaper to prepare for, and less uncertain. None of it is about getting rid of the gatekeeper.
Addendum: Full disclosure, I did some consulting with ARPA-H on related work. See also my previous post on the a radical deregulatory approach, Montana’s SB535 and a Potential Biotech Renaissance in America
The post Two Roads to Fast Clinical Trials, and the US Takes Neither appeared first on Marginal REVOLUTION.
2026-06-23 17:20:27
From a very credible Labour source:
– Wes Streeting promised the Chancellorship for not running.
– Capital gains raised to match income tax. Possible exit tax.
– Economic focus: devolution, plus state ownership of cost-of-living essentials (energy, water, transport).
– Nothing on AI or tech, bar higher capital gains and an EIS/SEIS-style relief for backing British businesses. (Spoiler: startups now incorporate in Delaware and raise on SAFEs. I’ve done 60+ angel investments; only two were eligible.)
Andy and Wes don’t seem to grasp that tech has been the core engine of growth for 20 years, and AI will only accelerate that.
So why would any founder build here? How does the UK compete with the US and China on AI? Where does growth actually come from?
The world economy is changing fast, and we need to be ready to thrive in it, not just survive.
I really hope this admin appoints some figures who actually get what’s happening. Losing business support early, from a disastrous first budget, was the beginning of the end for Starmer.
So, in a nutshell, no, the UK is not improving.
The post Is the UK improving? appeared first on Marginal REVOLUTION.
2026-06-23 15:07:53
He starts his new essay with this:
In 2014 I wrote in The New York Times that if your own team is not in the World Cup, you should root for the one whose victory would do the most good. Add up the happiness a title would create, more where more people care, more where incomes are lower, and more where a win would be a first rather than a habit, and root for the country on top. That year it was Nigeria. With 48 teams in 2026, and more of the world’s poorer and first-time sides in the field, I rebuilt the guide, with more nuance and, thanks to AI, at a fraction of the old cost. It updates itself as the games are played.
At least for now, you should root for the DRC he argues.
The post Dean Karlan has a Substack appeared first on Marginal REVOLUTION.